UK Markets closed

Allarity Therapeutics A/S (ALLR.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
2.7100-0.1380 (-4.85%)
At close: 05:29PM CET

Allarity Therapeutics A/S

Venlighedsvej 1
Horsholm 2970
Denmark
45 88 74 24 14
http://www.allarity.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees14

Key executives

NameTitlePayExercisedYear born
Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D.Co-Founder546.08kN/A1955
Dr. Steen Meier KnudsenFounder & Chief Scientific Officer185.11kN/A1961
Ms. Ulla Hald BuhlFounder, COO, Chief IR & Communications370.22kN/A1964
Mr. Stefano R. CarchediCEO, Pres & DirectorN/AN/A1962
Mr. Thomas JensenFounder & Sr. VP of Information TechnologiesN/AN/A1978
Mr. Claus Frisenberg PedersenChief Commercial OfficerN/AN/A1972
Mr. Jens Erik Knudsen CPA, M.B.A.Chief Financial OfficerN/AN/AN/A
Mr. James G. CullemSr. VP of Corp. Devel.N/AN/AN/A
Ms. Annie RasmussenChief of Clinical OperationsN/AN/A1957
Dr. Marie FoeghChief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Allarity Therapeutics A/S develops drugs for the treatment of cancer using drug-specific companion diagnostics. Its product pipeline includes stenoparib, a PARP inhibitor in Phase II clinical trials for the treatment of ovarian cancer, as well as in pre-clinical studies for the treatment of coronavirus; dovitinib, a pan-tyrosine kinase inhibitor in post-Phase III clinical trials for treatment renal cell carcinoma; and IXEMPRA, a microtublin inhibitor, which is in Phase II clinical for treatment of metastatic breast cancer. The company is also developing LiPlaCis, a liposomal formulation of cisplatin in Phase II clinical trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin for the treatment of brain cancer; and Irofulven, a DNA damaging agent in Phase II clinical trials for prostate cancer. The company was formerly known as Oncology Venture A/S and changed its name to Allarity Therapeutics A/S in October 2020. Allarity Therapeutics A/S was founded in 2004 and is headquartered in Hørsholm, Denmark.

Corporate governance

Allarity Therapeutics A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.